Biography
Dr. Krishna is currently Professor and Director of Pharmacology at the College of Osteopathic Medicine, Touro University in Nevada. He obtained a Bachelor of Science (First Class Honors) in Pharmacology and Physiology and a Doctor of Philosophy, Medicine (OB/GYN/Pharmacology) from Monash University in Australia. Dr. Krishna also teaches for the Step 1 USMLE and COMLEX reviews for Kaplan Medical throughout the United States and in UAE, Europe, Saudi Arabia, India, Mexico and the Caribbean. He has been teaching online for Kaplan University for over 7 years and is the contributing author for Kaplan Medical’s Pharmacology Review Book. He has contributed to numerous publications and is a member of a number of organizations including Fellow-American College of Clinical Pharmacology.
Research Interest
His research background is in maternal and neonatal pharmacology specifically looking at materno-fetal transfer utilizing the perfused human placental and cultured syncytiotrophoblast model. Complimentary and Alternative medicine is another area of interest.
Biography
Michael Retsky (PhD in Physics from University of Chicago) made a career change to cancer research thirty years ago. . He was Prof of Biology at University of Colorado and Visiting Prof of Medical Oncology at University of Texas. He is Research Associate at Harvard TH Chan School of Public Health and Honorary Reader at University College London. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. Retsky is Editor of a Springer-Nature book on a breast cancer project published July 2017. After diagnosis of stage IIIc colon cancer in 1994, he was the first person to use what is now called metronomic adjuvant chemotherapy. He is a founder and for 10 years was on the Board of Directors of the Colon Cancer Alliance. He has published more than 70 papers in physics and cancer.
Research Interest
Research interest A bimodal pattern of hazard of relapse among early stage breast cancer patients has been identified in multiple databases from US, Europe and Asia, studying these data to determine if this can lead to new ideas on how to prevent relapse in breast cancer, Using computer simulation and access to a very high quality database from Milan for patients treated with mastectomy only.

Alain L. Fymat
Professor
INTERNATIONAL INSTITUTE OF MEDICINE AND SCIENCE, INC
USA
Biography
Dr. Alain L Fymat is a medical-physical scientist and an educator. He was educated at the University of Paris-Sorbonne and the University of California at Los Angeles. He is the current President/CEO and Professor at the International Institute of Medicine and Science with a previous appointment as Executive Vice President, Chief Operating Officer and Professor at the Weil Institute of Critical Care Medicine. He was formerly Professor of Radiology, Radiological Sciences, Radiation Medicine (Oncology), Critical Care Medicine, and Physics at several U.S. and European Universities. Previously, he was Deputy Director (Western Region) of the U.S. Department of Veterans Affairs, Veterans Health Administration (Office of Research Oversight), and Director of the Magnetic Resonance Imaging Center and for a time Acting Chair of Radiology at its Loma Linda, California Medical Center. He has extensively published (~ 425 publications including patents, books & monographs, book chapters, refereed articles) and has lectured extensively in the USA, Europe, Africa and Asia. He has been the recipient of numerous research grants from government, academia and private industry, and has consulted extensively with these entities. He is a Board member of several institutions and Health Advisor of the American Heart & Stroke Association (Coachella Valley Division, California). He is Editor-in-Chief, Honorable Editor or Editor of 25 scientific Journals
Research Interest
Dr. Fymat’s current research interests lie at the interface between science and medicine, particularly cancer/oncology, molecular/personal/precision medicine, nanomedicine, human genetics/ epigenetics/ ecogenetics, neurodegenerative diseases, and pharmacogenomics. His most recent publications deal with nanotechnology and cancer, nanochemotherapy, nanoneurology, natural and synthetic immunotherapy, drug delivery across the brain protective barriers, and neurodegenerative disorders.